Controlled Drugs and Substances Act Loi Réglementant Certaines
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Genl:VE 1970 © World Health Organization 1970
Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse. -
Emergency Department Requirement for Assessment of Outpatients Who Receive Injectable Narcotics
This is an Interior Health CONTROLLED document. A copy of this document in paper form is not controlled and should be checked against the electronic file version to ensure accuracy Administrative Policy Manual Code: AH Patient/Client Relations/Care AH0600 - EMERGENCY DEPARTMENT REQUIREMENT FOR ASSESSMENT OF OUTPATIENTS WHO RECEIVE INJECTABLE NARCOTICS 1.0 PURPOSE To promote quality care and patient safety by ensuring Outpatients are appropriately assessed by an EDP or MRP when receiving or prior to receiving an injectable Narcotic in Emergency Departments (ED) of Interior Health (IH). 2.0 DEFINITIONS EDP Emergency Department Physician MRP Most Responsible Physician Narcotic Any substance set out in the schedule or anything that contains any substance set out in the schedule in the (Narcotic Control Regulations, CRC. C., 1041), see Appendix B. Outpatient A patient who presents to the ED for care and is not hospitalized or admitted to hospital. 3.0 POLICY 3.1 Assessment and Order Required This policy applies to Narcotic injection(s) administered to Outpatients being treated for acute and/or chronic conditions at IH EDs. Narcotic injection(s) will only be administered to Outpatients when the Outpatient has been assessed by an EDP/MRP (with active privileges in the administering facility) and the EDP/MRP has written an order dated within 24 hours of the Narcotic injection being administered. NOTE: Phone orders are acceptable on the undertaking the EDP/MRP will assess the Outpatient within 24 hours of the phone order. Orders for a series of Narcotic injections in excess of 24 hours require Outpatients be reassessed by an EDP/MRP (with active privileges in the administering facility) within 24 hours of the initial order and within every 24 hours thereafter while the Narcotic injection order is in effect. -
EB30 17 Eng.Pdf (932.3Kb)
W Ü K L Ü Г!匕 A L_ Í H ORGAN¡SATION ívlОND¡ALE ORGANIZATION DE LA SANTE EXECUTIVE BOARD EB30/17 “ Thirtieth Session 28 May 1962 Provisional agenda item 3.5 ORIGINAL: ENGLISH ACTION IN RESPECT OF INTERNATIONAL CONVENTIONS ON NARCOTIC DRUGS 1 The Seventh Wcrld Health Assembly, in resolution WHA7.6, decided that the Direсtor-General, upon receipt of the appropriate expert advice, should take decisions as to the classification of substances under certain international agree- ments, and that he should inform the Executive Board of all such decisions • The Director-General accordingly has the honour to inform the Board that, after having received advice from the Expert Committee on Addiction-Producing 2 Drugs, he has forwarded to the Secretary-General of the United Nations: (l) as required by Article 1 of the Protocol of 19 November 19^*8 bringing under international control drugs outside the scope of the Convention of 13 July 19)1 for Limiting the ^Manufacture and Regulating the Distribution of Narcotic Drugs, as amended by the Protocol signed at Lake Success on 11 December 19^6, nine notifications concerning the following drugs: (-)-3-h.ydroxy-N-propargylmorphinan 3 mete thohe p taz i ne metheptazine 3 methadone-intermediate 3 moramide-intermediate 3 noracymethadol oxpheneridine pethidine-intermediate-Bpethidine-intermediate-Aj) 3 1 Handbook of Resolutions and Decisions, 5th ed” p. 19, resolution WHA7-6. 2 Twelfth Report, Expert Committee on Addiction-Producing Drugs, Section 1 published as Wld Hlth Org, techn. Rep. Ser. 229 Proposed international non-proprietary name; for chemical formula, see twelfth report, Expert Committee on Addiction-Producing Drugs published as Wld Hlth Org, techn. -
Narcotic Drugs and Psychotropic Substances (Control) Act
LAWS OF GUYANA Narcotic Drugs and Psychotropic Cap. 35:11 3 Substances (Control) CHAPTER 35:11 NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES (CONTROL) ACT ARRANGEMENT OF SECTIONS PART I PRELIMINARY SECTION 1. Short title. 2. Interpretation. PART II PROHIBITION OF POSSESSION OF AND TRAFFICKING IN NARCOTICS AND CULTIVATION OF CERTAIN PLANTS 3. Definitions for Part II. 4. Penalty for possession of narcotic. 5. Penalty for trafficking in narcotic. 6. Penalty for supply, etc., of narcotic to child or young person if death results from consumption or administration of it. 7. Penalty for bringing into prison or taking out of prison, etc., of a narcotic. 8. Penalty for cultivation of certain plants. 9. Procedure for purposes of section 8(2) to (6). 10. Power of entry in respect of State or Government lands. 11. Power of destruction of prohibited plants. 12. Penalty for certain other acts connected with narcotics. 13. Certain prescriptions to be unlawful. 14. Penalty for receiving additional narcotic or prescription without disclosure of earlier receipt. 15. Removal of name from register. L.R.O. 3/1998 LAWS OF GUYANA 4 Cap. 35:11 Narcotic Drugs and Psychotropic Substances (Control) PART III NARCOTICS IN TRANSIT SECTION 16. Definitions for Part III. 17. Prohibition against sending narcotics by post. 18. Narcotics in transit. 19. Control of Comptroller over narcotics brought into Guyana in transit. 20. Tampering with narcotics in transit. 21. Diversion in Guyana of narcotics in transit. 22. Variations in export authorisation, import authorisation or diversion certificate granted in country other than Guyana. PART IV LICENCES 23. Grant and renewal of licences. -
On the Approximation of the Laws of the Member States Relating to Cosmetic Products (76/768/EEC )
27 . 9 . 76 Official Journal of the European Communities No L 262/169 COUNCIL DIRECTIVE of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products (76/768/EEC ) THE COUNCIL OF THE EUROPEAN COMMUNITIES, regards the composition, labelling and packaging of cosmetic products ; Having regard to the Treaty establishing the Euro pean Economic Community, and in particular Whereas this Directive relates only to cosmetic prod Article 100 thereof, ucts and not to pharmaceutical specialities and medicinal products ; whereas for this purpose it is necessary to define the scope of the Directive by Having regard to the proposal from the Commission, delimiting the field of cosmetics from that of phar maceuticals ; whereas this delimitation follows in particular from the detailed definition of cosmetic Having regard to the opinion of the European Parlia products, which refers both to their areas of appli ment ( 1 ), cation and to the purposes of their use; whereas this Directive is not applicable to the products that fall Having regard to the opinion of the Economic and under the definition of cosmetic product but are Social Committee (2 ), exclusively intended to protect from disease; whereas, moreover, it is advisable to specify that certain prod ucts come under this definition, whilst products Whereas the provisions laid down by law, regulation containing substances or preparations intended to be or administrative action in force in the Member ingested, inhaled, injected or implanted in the human States -
Questions & Answers
SERVING CANADIANS Research and Statistics Division questions & answers February 2003 www.canada.justice.gc.ca/en/ps/rs Drug Use and Offending by: Nathalie Quann, Research Analyst Q1. How has drug legislation changed recently? Table of Contents Q1. How has drug legislation changed recently? .................................................1 Since May 1997, the Controlled Drugs and Substances Act governs all drug offences in Canada. Q2. What are the most recent Canadian statistics on drug use? ............................2 Prior to 1997, the two most important federal statutes dealing with Q3. What is the public attitude towards illicit drugs were the Narcotics Control Act (NCA) and the Food and decriminalization of drugs? ...................4 Drugs Act (FDA). The Narcotics Control Act governed over 120 different types of drugs such as cocaine, heroin, opium, and Q4. What do Canadians think about the cannabis. The NCA did not distinguish one drug from another. For medical use of soft drugs? ......................5 example, cannabis and cocaine offenders were subject to the same Q5. How is the health care system affected criminal procedures and penalties. The Food and Drugs Act governed by drug use and abuse? ..........................5 the regulation of pharmaceutical drugs, food, cosmetics, and medical devices. Two parts most specifically dealt with the non-medical use Q6. How many drug offences were reported of specific drugs: Part III governed "controlled drugs" (such as by the police in 2000? ............................6 amphetamines, barbiturates, testosterone) while Part IV governed Q7. Are offenders always charged by the "restricted drugs" (such as LSD, and other hallucinogenic drugs). police when drugs are involved? ...........7 The maximum penalties were less strict under the FDA than the NCA. -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9 -
Marrakesh Agreement Establishing the World Trade Organization
No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX -
(12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2. -
Dangerous Drugs Act
MINISTRY OF THELAWS ATTORNEY OF TRINIDAD GENERAL AND AND LEGAL TOBAGO AFFAIRS www.legalaffairs.gov.tt DANGEROUS DRUGS ACT CHAPTER 11:25 Act 38 of 1991 Amended by 27 of 1994 173/1995 44 of 2000 *55 of 2000 11 of 2014 *See Note on page 2 Current Authorised Pages Pages Authorised (inclusive) by L.R.O. 1–2 .. 3–10 .. 11–12 .. 13–16 .. 17–46 .. 47–94 .. UNOFFICIAL VERSION L.R.O. UPDATED TO 31ST DECEMBER 2016 MINISTRY OF THE ATTORNEY GENERALLAWS OF AND TRINIDAD LEGAL AFFAIRS AND TOBAGOwww.legalaffairs.gov.tt 2 Chap. 11:25 Dangerous Drugs Index of Subsidiary Legislation Page Dangerous Drugs (Appointment of Inspectors) Order (LN 143/2001) … 47 Note on section 60 of Act Section 60 of the Act provides as follows: “60. (1) The following written laws are repealed: (a) the Narcotic Control Ordinance; and (b) the Narcotic Drugs and Psychotropic Substances Control Act, 1985. (2) Notwithstanding the repeal of the Ordinance and the Act referred to in subsection (1) anything done or any action taken under the Ordinance or the Act, shall be deemed to have been done or taken under the corresponding provisions of this Act.”. N.B. Subsidiary Legislation saved in respect of the above repealed statutes: 1. Dangerous Drugs Ordinance (Ch. 12. No. 6) (1950 Revised Edition)— (Repealed by Ord. No. 27 of 1961)— (a) Raw Opium and Ganja Regulations (1950 Rev. Ed.) Vol. 8 at page 521; (b) Dangerous Drugs Regulations (1950 Rev. Ed.) Vol 8 at page 515; (c) Power of Inspection Order 1963 (LN 104/1963). -
ATP, 489 Absolute Configuration Benzomotphans, 204 Levotphanol
Index AIDA, 495 Affinity labeling, analogs of (Cont.) cAMP, 409, 489 motphine,448 ATP, 409, 489 naltrexone, 449 [3H] ATP, 489 norlevotphanol,449 Absolute configuration normetazocine, 181 benzomotphans, 204 norpethidine, 232 levotphanol, 115 oripavine, 453 methadone and analogs, 316 oxymotphone, 449 motphine, 86 K-Agonists, 179,405,434 phenoperidine, 234 Aid in Interactive Drug Analysis, 495 piperazine derivatives, 399 [L-Ala2] dermotphin, 363 prodines and analogs, 272 [D-Ala, D-Leu] enkephalin (DADL), 68, 344 sinomenine, 28, 115 [D-Ala2 , Bugs] enkephalinamide, 347, 447 viminol, 400 [D-Ala2, Met'] enkephalinamide, 337, 346, Ac 61-91,360 371,489 Acetylcholine, 5, 407 [D-Ala2]leu-enkephalin, 344, 346, 348 Acetylcholine analogs, 186, 191 [D-Ala2] met-enkephalin, 348 l-Acetylcodeine, 32 [D-Ala2] enkephalins, 347 Acetylmethadols (a and (3) Alfentanil, 296 maintenance of addicts by a-isomer, 304, 309 (±)-I1(3-Alkylbenzomotphans, 167, 170 metabolism, 309 11(3-Alkylbenzomotphans, 204 N-allyl and N-CPM analogs, 310, 431 7-Alkylisomotphinans, 146 stereochemistry, 323 N-Alkylnorketobemidones, 431 synthesis, 309 N-Alkylnorpethidines, 233 X-ray crystallography, 327 N-Allylnormetazocine, 420 6-Acetylmotphine, receptor binding, 27 N-Allylnormotphine, 405 Acetylnormethadol, 323 N-Allylnorpethidine, 233 8(3-Acyldihydrocodeinones, 52 3-Allylprodines (a and (3), 256 14-Acyl-4,5-epoxymotphinans, 58 'H-NMR and stereochemistry, 256 7-Acylhydromotphones, 128 X-ray crystallography, 256 Addiction, 4 N-Allylnormetazocine, 420 Adenylate cyclase, 6, 409, 413, 424,